| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fede5e271fe9a3788b900c0ce6e0054 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d628157b02cf53666a28078a2cfb673a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9caea78006a9f77a2d7b27dad0e4a433 |
| publicationDate |
2018-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2018003459-A |
| titleOfInvention |
TREATMENT WITH TRASTUZUMAB VC-SECO-DUBA OF CANCER PATIENTS REFRACTORY TO TRASTUZUMAB EMTANSINA. |
| abstract |
The present invention relates to trastuzumab vc-seco-DUBA (SYD985) of the antibody-drug conjugate (ADC) containing duocarmycin for use in the treatment of HER2 IHC 3+ or HER2 IHC 2 + / FISH positive cancer patients refractory to trastuzumab emtansin (T-DM1), particularly of breast cancer patients refractory to T-DM1. |
| priorityDate |
2015-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |